Poolbeg Pharma, a biopharmaceutical company specialising in the development and commercialisation of medicines targeting rare and orphan diseases, today announces that independent research conducted on its behalf confirms a >$10 billion market opportunity for POLB 001 in Cancer Immunotherapy-Induced CRS as an orally delivered preventative therapy.
Cancer immunotherapies have been approved in rare and orphan blood cancers, so the Company can see potential for POLB 001 in one or more of these cancer types.
POLB 001 will be developed for use in cancer immunotherapy-induced CRS.
Rare and orphan diseases represent a significant area of unmet need for patients, as they are often understudied.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
